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NANOPARTICLE-MEDIATED METHODS 
FOR ANTIMICROBIAL SUSCEPTIBILITY 
TESTING OF BACTERIA 
RELATED APPLICATION 
This application claims priority from co-pending provi-
sional application Ser. No. 60/982,529, which was filed on 25 
Oct. 2007, and which is incorporated herein by reference in its 
entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
This invention was made with govermnent support under 
KOi CAI 01781 awarded by the National Institutes of Health. 
The government has certain rights in the invention. 
FIELD OF THE INVENTION 
The present invention relates to the field of infectious dis-
eases and, more particularly, to methods of determining the 
susceptibility of cells, particularly bacterial cells, to a poten-
tial treatment agent such as an antibiotic. 
BACKGROUND OF THE INVENTION 
The identification and administration of an effective anti-
microbial agent is of the utmost importance in clinical and 
point-of-care patient settings. Specifically, with the emer-
gence of multi-drug resistant bacterial strains, such as methi-
cillin-resistant Staphylococcus aureus (MRSA) and multiply 
drug resistant tuberculosis (XDR-TB), identifying the most 
effective antibiotic and administering it to the patient at con-
centrations that will kill or inhibit bacterial growth without 
undermining the patient's health is important. 
Currently, the assessment of antimicrobial susceptibility 
relies on the isolation of the microorganism, followed by an 
attempt to grow the pathogen in the presence of various anti-
biotic agents and different concentrations thereof. A major 
problem with this approach is that it requires at least 24 hours 
in order to provide qualitative and quantitative information 
associated with the effectiveness of the antibitiotic. In the 
meantime, even though physicians will institute treatment on 
clinical grounds and without waiting for the lab results, the 
patient might face severe complications and worsening of 
his/her pathological condition due to growth and pathogen-
esis induced by the microorganism and inability of the 
immune system to respond in an effective way. As mentioned 
before, typically, physicians caring for the hospitalized 
patient must start antibiotic treatment based only on experi-
ence and clinical hunches, since the results of in vitro antibi-
otic susceptibility tests will not be available for 48-72 hours 
after initial cultures are taken. 
Therefore, the need of fast and accurate antimicrobial sus-
ceptibility assessment modalities remains, even in this day of 
modern medical advances. Additionally, apart from clinical 
and point-of-care diagnostics, the pharmaceutical industry is 
under pressure to continue development of novel, sensitive 
and rapid antimicrobial susceptibility assays. Hence, having 
methods to facilitate high-throughput screening of candidate 
antibiotics, while using small sample volumes, could reduce 
the costs associated with drug development and expedite the 
drug development process. 
SUMMARY OF THE INVENTION 
With the foregoing in mind, the present invention advan-
tageously provides a novel, rapid and sensitive method for 
2 
testing the effect of a treatment agent upon a cell's metabo-
lism. The methods of the invention are eminently applicable 
to antibiotic susceptibility testing of bacterial isolates. Addi-
tionally, the disclosed methods may also be employed to test 
an agent for its effect on the metabolism of cells, whether the 
cells are bacterial cells or the cells of higher organisms, 
including mammalian cells in culture. 
Significant efforts have been made for the development of 
biosensors, capable of detecting biological targets, such as 
10 proteins, nucleic acids, viruses and bacteria. The aggregation 
of metallic nanoparticles, induced by specific biomolecular 
interactions, has been employed in the development of simple 
and sensitive biosensors with potential applications in immu-
noassays. Noble metal nanoparticles, in particular gold nano-
15 particles (AuNPs), have recently been the focus of extensive 
studies in this field, due to their extraordinary optical and 
electronic properties. 
Gold nanoparticles exhibit a strong surface plasmon reso-
nance band, as a consequence of collective oscillations of the 
20 surface electrons, which are induced by the incident electro-
magnetic radiation. On the other hand, iron-oxide-based 
magnetic nanocrystals have been widely used in a variety of 
biomedical applications, for example, in diagnostics, mag-
netic resonance imaging (MRI) and magnetically-guided 
25 site-specific drug delivery systems. Notably, the use of mag-
netic nanoparticles in the fast and reliable detection of a 
specific bacterium in complex biological media (blood and 
milk) has been recently reported. 
The working mode of these nanosensors relies on the phe-
30 nomenon where in the presence of a target these nano sensors 
self-assemble, that is, they agglutinate. The induction of 
nano-assembly formation results in a concomitant significant 
change in the surface plasmonresonance of noble metal nano-
particles (either gold or silver). In the case of magnetic nano-
35 particles (such as iron oxide), there is a dramatic effect on the 
spin-spin relaxation time (T2) of neighboring water mol-
ecules' protons. 
Based on the above behavior, we have developed a quick 
and facile assay for the assessment of antimicrobial suscep-
40 tibility, using either gold or iron oxide nanoparticles (IONPs) 
coated with a polysaccharide layer preferably but not exclu-
sively composed of polymerized dextran. Particularly, the 
detection principle relies on the fact that in the presence of an 
effective antibiotic (bactericidal or bacteriostatic) and at 
45 inhibitory concentrations, there is suppression of the bacterial 
metabolism and reduction in nutrient uptake (i.e. carbohy-
drates). Hence, the concentration of the nutrients, such as 
starch and other carbohydrates, remains higher when com-
pared to those under non-inhibitory antibiotic concentrations, 
50 antibiotic resistance, antibiotic incompetence or absence of 
an inhibitory compound. Therefore, after incubating the 
nanoparticle-specimen suspension in the presence of Con-
canavalin A (Con A), it is possible to assess the metabolic 
activity of the cells, based on the concentration of carbohy-
55 drate remaining, which is related to the changes in T2 or 
surface plasmon resonance band. 
The presently described methods have several advantages 
over existing methodology. The present methods are facile 
and cost effective. Preparation of the nanoparticles does not 
60 require the use of toxic reagents, and therefore the synthe-
sized nanoparticles are environmentally friendly and non-
toxic to the assay's user. Good stability of the resulting par-
ticles over prolonged storage in water, phosphate buffered 
saline and citrate buffer, makes them suitable for use at the 
65 points-of-care and under harsh conditions. The resulting gold 
and iron oxide particles can be concentrated using ultrafiltra-
tion devices without inducing agglomeration of the nanopar-
US 9,057,094 Bl 
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ticles. Polysaccharide-coated gold and iron oxide nanopar-
ticles can be used to assess bacterial metabolism fast and 
accurate with available instrumentation, based on the con-
sumption of carbohydrates in the culture medium. Dextran-
coated gold and iron oxide nanoparticles can be used to assess 
antimicrobial susceptibility and an antibiotic's minimum 
inhibitory concentration (MIC), based on the consumption of 
carbohydrates by the microorganisms, without relying on the 
expression of reporter genes. Dextran-coated gold and iron 
oxide nanoparticles can fast and reliably assess the state of 
bacterial metabolism and antimicrobial susceptibility, requir-
ing a fraction of the time needed by such standard methods as 
the turbidity test, disc diffusion assay, and plate growth). 
Dextran-coated gold and iron oxide nanoparticles can deter-
mine bacterial metabolism and antimicrobial susceptibility 
using small sample volumes (about 10 µL ), which is useful for 
the screening of expensive antimicrobial agents and growth in 
specialized culture media. 
4 
tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
FIG. 1 is a TEM image of dextran-coated (a) gold and (b) 
iron oxide nanoparticles according to an embodiment of the 
present invention; the TEM images show that the gold nano-
particles are spherical, whereas the iron oxide particles are 
rods; 
FIG. 2 shows a proposed model for gold nanoparticle 
10 (AuNP) mediated antimicrobial susceptibility assessment; in 
the absence ofbacterial metabolism (B) or under sterile con-
ditions (C), addition ofConcanavalinA (ConA) results in the 
formation of extensive nanoassemblies and large shifts in the 
15 
surface plasmon band oftheAuNPs due to the contribution of 
free carbohydrates; bacterial metabolic activity is associated 
with lower shifts in the plasmonic band due to the formation 
of smaller nanoassemblies; the trend described herein is pre-
dicted to be similar when other metallic nanoparticles are 
20 used (for instance, silver) observing similar changes in sur-
face plasmon peak; in addition, the same behavior is observed 
when magnetic polysaccharide-coated nanoparticles (such as 
iron oxide) are used, however in this case changes in water 
Dextran-coated gold and iron oxide nanoparticles can 
assess antimicrobial susceptibility in an affordable, high-
throughput setting, supporting expedited decision making. 
The nanoparticles of the present invention can be used in the 
field and at the point-of-care to assess antimicrobial suscep-
tibility, as they are stable over a wide range of temperatures 25 
and do not require special storage conditions. The dextran-
coated nanoparticles can determine antimicrobial suscepti-
bility using bacteria isolated from clinical and environmental 
specimens, without the need to use engineered or sensitive 
strains. The dextran-coated nanoparticles can facilitate anti- 30 
microbial susceptibility, without the use of radioactive or 
hazardous materials. etermination of antimicrobial activity 
can be performed with either a simple UV-Vis spectropho-
tometer or a miniaturized, portable NMR, using gold and iron 
oxide nanoparticles respectively. 
relaxation time are observed; 
FIG. 3 illustrates the UV-Visible spectra of gold nanopar-
ticles in non-assembled conditions; 
FIG. 4 depicts that AuNPs' spectral characteristics are 
independent of the antibiotic concentration, under Con-
canavalin A-induced clustering; 
FIG. 5 shows that in the absence ofConA, theAuNPs were 
in a non-assembled state, exhibiting the same spectral char-
acteristics, regardless of the presence of bacteria and antibi-
otic; samples with ampicillin (64, 8, and 2 µg) and the bacte-
rial growth control (0 µg ampicillin) contained aliquots from 
35 liquid cultures initially inoculated with 106 CFU of E. coli; 
FIG. 6 presents the shift of the gold nanoparticles' surface 
plasmon band at (A) low (non-inhibitory, 2 µg) and (B) high 
(inhibitory, 64 µg) ampicillin concentrations; 
Accordingly, the present invention provides a method of 
testing bacterial cells for antimicrobial susceptibility. The 
method comprises preparing a suspension of the bacterial 
cells in a non-nutrient medium and mixing with the suspen-
sion an antimicrobial, a carbohydrate usable by the bacterial 
cells, metallic nanoparticles, and a lectin. The method con-
tinues by incubating the mixture while monitoring a param-
eter of the nanoparticles responsive to use of the carbohydrate 
by the bacterial cells. 
More broadly stated, the invention discloses a method of 
testing an agent for its effect on cell metabolism. This 
embodiment of the invention includes preparing a suspension 
of cells in a non-nutrient medium, mixing the suspension with 
the agent, adding a carbohydrate usable by the cells, metallic 
nanoparticles, and a lectin with binding specificity for the 
added carbohydrate, and monitoring a nanoparticle param-
eter responsive to the cells. 
Yet another variation in the present invention includes a 
method of monitoring the metabolism of cells. This method 
comprises preparing a suspension of the cells in a non-nutri-
ent medium, mixing the suspension with metallic nanopar-
ticles bearing a lectin, adding to the suspension a carbohy-
drate metabolizable by the cells and monitoring the 
nanoparticles for a parameter responsive to metabolism of the 
carbohydrate by the cells. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
apparent as the description proceeds when taken in conjunc-
FIG. 7 shows the shift of the gold nanoparticles' surface 
40 plasmon band at low (non-inhibitory, 2 µg) and high (inhibi-
tory, 64 µg) ampicillin concentrations, while using higher 
amount of AuNPs ( 50: 50 AuNP:dH20 v:v ); 
FIG. 8 is a determination of the MIC using (A) the surface 
plasmon peak shift of Au NPs and (B) the turbidity method 
45 (original photograph, numbers indicate the amount of ampi-
cillin); 
FIG. 9 is a determination of MIC in high-throughput for-
mat using Au-NP and Con A; purple squares indicate absence 
of bacterial metabolism, green areas demonstrate inhibition 
50 of bacterial metabolism, and red wells show active bacterial 
metabolism, similar to the data trend of Table 1; Group (a) 
Sterile Mueller-Hinton (MH) broth, (b) E. coli (106 CFU) 
grown in the absence ofampicillin, ( c) heat-inactivatedE. coli 
(106 CFU) in MH broth, (d) and (e) E. coli (106 CFU) grown 
55 in the presence of 64 and 2 µg ampicillin, respectively; fol-
lowing wells include replications of these groups, obeying the 
above pattern; Group (f) consists of additional control 
samples, similar to (a); 
FIG. 10 shows dose-dependent changes in T2 of dextran-
60 coated IONPs in the presence of Con A after a 30-minute 
incubation at room temperature; sigmoidal fit was applied 
with an R2=0.99 (OriginPro 7.5); similar results were 
obtained after 0-, 90- and 150-minute incubations; 
FIG. 11 shows that in the absence of ConA, the IO NPs 
65 were in a non-assembled state, exhibiting the same T2, 
regardless of the presence of bacteria. 1; water, 2; sterile 
medium (with starch), 3; sterile medium (no starch), 4; 102 
US 9,057,094 Bl 
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CFU of E. coli, 5; 103 CFU of E. coli, 6; 104 CFU of E. coli, 
7; 105 CFU of E. coli, 8; 106 CFU of E. coli, 9; 108 CFU of E. 
coli, 1 O; 109 CFU of E. coli; 
6 
testing of the present invention, suitable methods and mate-
rials are described below. Any publications, patent applica-
tions, patents, and other references mentioned herein are 
incorporated by reference in their entirety. In case of conflict, 
the present specification, including any definitions, will con-
trol. In addition, the materials, methods and examples given 
are illustrative in nature only and not intended to be limiting. 
Accordingly, this invention may be embodied in many differ-
ent forms and should not be construed as limited to the illus-
FIG. 12 shows dose-dependent changes in T2 of IONPs 
associated with starch consumption, due to various degrees of 5 
bacterial loads; the graph depicts data obtained after a 
30-minute incubation at room temperature, in the presence of 
Concanavalin A; sigmoidal fit was applied with an R2=0.99 
(OriginPro 7.5); similar results were obtained after 0- and 
90-minute incubations; 10 trated embodiments set forth herein. Rather, these illustrated 
embodiments are provided so that this disclosure will be 
thorough and complete, and will fully convey the scope of the 
invention to those skilled in the art. Other features and advan-
FIG. 13 depicts that the behavior ofIONPs is independent 
of the bacterial population, but it is dependent of active bac-
terial metabolism; the graph depicts data obtained after a 
30-minute incubation at room temperature, in the presence of 
Con A; linear fit was applied with an R2=0.14 (OriginPro 15 
7.5); similar results were obtained after 0-, 90- and 150-
minute incubations; 
FIG. 14 indicates that in the absence ofConA, the IONPs 
exhibited the same T2, regardless of the presence of bacteria 
and antibiotic, 1; water, 2; sterile medium (with starch), 3; 20 
sterile medium (no starch), 4; 64 µg ampicillin, 5; 8 µg ampi-
cillin, 6; 2 µg ampicillin; 7; 1 µg ampicillin, 8; 0 µg ampicillin; 
FIG. 15 is a determination of the minimum inhibitory 
concentration using (A) the changes in spin-spin relaxation 
times (iH2) and (B) the turbidity method (original photo- 25 
graph, numbers indicate the amount of ampicillin); a similar 
trend was observed after 0- and 45-minute incubation at room 
temperature; the dotted line indicates the threshold of the 
drug's successful inhibition; 
FIG. 16 is a determination of the minimum inhibitory 30 
concentration of Shigella sonnei using the changes in spin-
spin relaxation times (li. T2) after a 30-min incubation at 25° 
C.; the dotted line indicates the threshold of the drug's suc-
cessful inhibition; 
FIG. 17 shows an assay of antibiotic resistance of Serratia 35 
marcescens using the changes in spin-spin relaxation times 
(li.T2) after a 30-min incubation at 25° C.; the dotted line 
indicates the threshold of the drug's successful inhibition; 
FIG. 18 shows a schematic representation of the assess-
ment of antimicrobial susceptibility using Concanavalin 40 
A-conjugated polysaccharide nano sensors using a silica coat-
ing where the direct conjugation of Con A to the capping 
matrix results in a non-competition based assay format; 
FIG. 19 shows kinetic profiles of the dextran-coated 
nano sensors and Con-A conjugated nano sensors where point 45 
A is the end-point of the dextran-coated nanosensors and 
point Bis the end-point of of the Con-A conjugated nano sen-
sors; and 
tages of the invention will be apparent from the following 
detailed description, and from the claims. 
Portions of the disclosure made herein have been published 
in the scientific literature, as follows. Dextran-Coated Gold 
Nanoparticles for the Assessment of Antimicrobial Suscepti-
bility; S. Nth, C. Kaittanis, A. Tinkham and J. M. Perez; 
Analytical Chemistry, 2008, 80, 1033-1038 (published on 
Web Jan. 17, 2008). Rapid Nanoparticle-Mediated Monitor-
ing of Bacterial Metabolic Activity and Assessment of Anti-
microbial Susceptibility in Blood with Magnetic Relaxation; 
C. Kaittanis, S. Nath and J. M. Perez; Plos One, September 
2008, Vol. 3, Issue 9, e3253 (an Internet publication available 
at www.plosone.org). As noted above, both of these scientific 
articles are incorporated herein by reference in their entirety 
and are intended to constitute part of this disclosure. 
Bacterial Cultures 
In order to investigate if the dextran-coated iron oxide 
nanoparticles can monitor the starch utilization due to bacte-
rial metabolic activity, different populations of Escherichia 
coli (strain 8739 fromATCC) were grown in starch-contain-
ing MH broth (DIFCOTM, BD) for 2 hours at 37° C. For 
determination of the minimum inhibitory concentration, 
Escherichia coli (106 CFU), Serratia marcescens (ATCC, 
106 CFU) and Shigella sonnie (strain 9290 from ATCC, 
106CFU) were grown in a starch-containing MH broth (DIF-
COTM, BD), for 2 hours at 37° C. in the presence or absence 
of ampicillin. For determination of MIC in blood, bacterial 
stocks (106 CFU) were grown in the presence or absence of 
ampicillin in a 5%-blood-supplemented starch-containing 
MH broth, for 2 hours at 3 7° C. Defibrinated sheep blood was 
obtained from the Colorado Serum Company, simulating bac-
terial isolation and growth in typical blood agar plates. For 
studies requiring heat inactivation, E. coli bacteria wee auto-
claved in the culture tubes for 10 minutes. Upon incubation or 
inactivation, all bacterial stocks were placed in a Fisher 




All the reagents used were of AR (Analytical Reagent) 
grade. Nitrogen-purged double-distilled water was used 
FIG. 20 shows the antimicrobial susceptibility in blood 
using Con-A conjugated nano sensors in which (A) is a graph 50 
of the determination of E Coli 's ampicillin MIC in blood and 
(B) is a graph of the determination of Serratia marcescens' 
drug resistance in blood with the Con-A conjugatednanosen-
sors five minutes after addition of a bacterial aliquot into the 
nanoparticle solution (Means±SE; p<0.05). 55 throughout the reaction. Iron salts, FeC12 .4H2 0 and 
FeC13 .6H2 0, were obtained from Fluka. Dextran (MW 10 
kDa) was received from Amersham. TEOS: tetraethylortho-
silicate (Fluka), APTS: 3-(amino-propyl)triethoxysilane (Al-
drich) and THPMP: 3-(trihydroxysilyl)propylmethyl-phos-
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
60 phonate (Ge lest Inc) were used as received from the suppliers. 
Synthesis ofDextran-Coated Gold Nanoparticles (AuNPs): 
Gold nanoparticles were synthesized by boiling a mixture 
of aqueous solution of gold chloride (HAuC14 ) and dextran 
(10 k). Explicitly, 1 ml HAuC14 (10-
2 M) was mixed with 
65 aqueous solution of dextran (10 gin 100 ml H20) and heated 
to boil on a hot plate. The solution turned piuk within 10 min 
and exhibits a UV-visible band at 531 nm, attributed to the 
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that the nanoparticles' surface plasmon band would not be 
affected by the presence of media, under non-assembled con-
ditions. 
Subsequently, we determined if the presence of antibiotics 
formation of gold nanoparticles. Finally, the gold nanopar-
ticles were filtered and washed several times with distilled 
water through an Ami con cell (Millipore ultrafiltration mem-
brane YM-30 k) to remove the free dextran molecules. 
Synthesis of Aminated Silica Coated IO NPs: 
The aminated silica-coated iron oxide nanoparticles were 
prepared using a previously published protocol, with modifi-
cations in order to yield stable nanoparticles via a water-based 
synthesis. Specifically, iron oxide nanocrystals were formed 
via the alkaline precipitation method, by mixing a solution of 
iron salts (0.202 g FeC12 .4H2 0, 0.488 g FeCly6H2 0, 88.7 µL 
HCl in 2 mL distilled water) with an armnonium hydroxide 
solution (830 µl NH40H in 15 mL distilled water). Then, 20 
seconds after the initiation of the iron oxide nanocrystal for-
mation, a TEOS-THPMP-APTS solution was added (6180 
µL THPMP, 2680 µL TEOS, 670 µL APTS) under continuous 
vortexing. The as-synthesized nanoparticle suspensions were 
centrifuged to remove large particles. Both the amino-silica-
and dextran-coated nanoparticles were washed several times 
with distilled water and concentrated through an Amicon 
8200 cell (Millipore Ultrafiltration membrane YM-30 k). 
Finally, the nanoparticle suspensions were stored at 4° C. 
until further use. 
5 in the growing media had any effects on the shift of the surface 
plasmon band, under assembled conditions. Specifically, 10 
µL aliquots ofMH broth, with varying amounts of ampicillin, 
were incubated with gold nanoparticles ( 400 µL Au NPs in 
600 µL distilled water) for 30 minutes at room temperature in 
10 the presence ofl 0 µL ConcanavalinA (1 µg/µL). The samples 
were examined on a Cary 300 UV-Vis spectrophotometer, 
and the shift of the surface plasmon band was determined. 
The obtained data indicated that the shift of the surface plas-
15 mon resonance band is independent of the antibiotic's con-
centration, under concanavalin-induced assembled condi-
tions (FIG. 4). 
Considering that Con A has affinity towards molecules 
with carbohydrate moieties, we reasoned that any variations 
20 in the carbohydrate concentrations should be observable 
using a known amount of dextran-coated nanoparticles and 
Con A, based on the surface plasmon band shift. Hence, the 
shift of the gold nanoparticles' surface plasmon resonance 
band should have depended on bacterial metabolism and cor-
25 responded to the levels of free carbohydrates in the solution. ConcanavalinA was conjugated to the to aminated silica-
coated iron oxide nanoparticles in the following manner. Two 
milliliters of aminated silica coated iron oxide nanoparticles 
(R2=225 mM- 1s-1, [Fe]=0.47 mg/ml) were used for the con-
jugation of Con A to the nanoparticles' surface. Initially, in 1 
mL of cold MES buffer (0.1 M, pH 6.0) 4.8 mg EDC (Pierce) 
and 3 mg NHS (Pierce) were dissolved. Then, 2 mg of lyo-
philized Con A (Type V, Sigma) were dissolved in 2 mL cold 
MES buffer (0.1 M, pH 6.0). Subsequently, the Con A solu-
tion was mixed with the EDC/NHS solution, followed by a 
35 
3-minute low-speed rotary mixing at room temperature. 
Finally, the aminated silica-coated iron oxide nanoparticles 
were added to the Con A (amine-reactive NHS-ester form) 
solution, followed by periodical rotary mixing at low speed 
and storage at 4° C. The resulting Con A-conjugated silica- 40 
coated iron oxide nanoparticles were purified from any 
unbound protein via magnetic separation using an MES 
buffer-equilibrated (0.1 M) LS25 MACSH colunm (Miltenyi 
Biotec). 
To study this, E. coli (106 CFU) were incubated for 2 hours at 
3 7° C. in MH broth, in the presence of various concentrations 
of ampicillin. Then, 10 µL aliquots of these samples were 
added into the Au NPs suspension, as stated above. Despite 
30 the presence of bacteria and antibiotic, the samples exhibited 
identical absorption spectra, under non-assembled conditions 
(FIG. 5). 
After addition of Con A and a 30-minute incubation at 25° 
C., distinct spectral differences were observed. Interestingly, 
under a small, presumably non-inhibitory, antibiotic concen-
tration the shift in the band was low, compared to the sterile 
control (FIG. 6A). A similar trend was also observed in the 
sample where bacteria grew in the absence of the antibiotic. 
However, under high, most likely inhibitory, concentration 
the shift was large with a broader shoulder, resembling the 
sterile control (FIG. 6B). This behavior was due to the higher 
amount of free carbohydrates that have not been utilized by 
the bacteria as their metabolism was suppressed, promoting 
extensive concanavalin-induced Au NP clustering. Analo-
Synthesis ofDextran-Coated IO Nanoparticles (IO NPs): 
A mixture of iron salts 0.203 g FeC12 .4H2 0 and 0.488 g 
FeCl3 .6H20 inHCl solution (88.7 µ112 NHCl in2ml water) 
was added to NH4 0H (830 µl in 15 ml N2 purged deionized 
water) and stirred on a digital vortex mixer for 10 sec. Then, 
45 gous results were obtained when higher concentrations of Au 
NPs were used (FIG. 7). 
an aqueous solution of dextran ( 5 gin 10 ml water) was added 50 
to the mixture and stirred for 1 hr. Finally, the entire mixture 
was centrifuged for 30 minutes to remove large particles, 
whereas the supernatant was collected, filtered, and washed 
several times with distilled water through an Amicon cell 
(Millipore ultrafiltration membrane YM-30 k) to remove any 55 
free dextran molecules. 
Dextran-Coated Gold Nanoparticles for Antimicrobial Sus-
ceptibility: 
In order to determine if noble metal nanoparticles, like Au 
NPs', surface plasmon resonance band is affected by the 60 
presence of complex growing media, we added into the nano-
particle suspension ( 400 µLAu NPs in 600 µL distilled water) 
either 10 µL distilled water (black line) or 10 µL Mueller-
Hintro (MH) broth containing starch (red line). After exami-
nation of the samples on a Cary 300 UV-Visible spectropho- 65 
tometer (Varian Inc.), both samples exhibited the same 
surface plasmon peak (FIG. 3). This supported the hypothesis 
Accurate determination of the minimum inhibitory con-
centration (MIC) can prevent adverse side effects, such as 
renal toxicity. Considering that the contemporary MIC deter-
mination depends on a day-long process, we examined if Au 
NPs can yield results faster without sacrificing reliability. 
Initially, E. coli (106 CFU) were incubated for 2 hours at 37° 
C. in MH broth, in the presence of different concentrations of 
ampicillin. Then, aliquots of these samples were incubated 
with Au NPs for 30 minutes at 25° C., in the presence of Con 
A. Based on the shifts of the surface plasmon band, the MIC 
was determined to be 8 µg, as the corresponding surface 
plasmon band shift was statistically different than the control, 
containing bacteria growing in the absence of antibiotic (FIG. 
SA). Correlation with standard methods was achieved by 
inoculating serial dilutions of ampicillin in MH broth with E. 
coli, followed by a 24-hour long incubation at 37° C. Bacte-
rial growth was assessed based on the broth's turbidity, 
whereas absence of turbidity was an indicator of successful 
antimicrobial susceptibility. The lowest ampicillin concentra-
tion where the MH broth was clear, suggesting that no bacte-
ria proliferated, was 8 µg (FIG. SB). This concentration was 
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identical to the Au NP-determined MIC, though the Au NP-
based method yielded the same results much faster. 
Finally, the potential of our Au-NP-based assay for the 
determination of antimicrobial susceptibility in high-
throughput format was investigated. In these studies, samples 
ofheat-inactivatedE. coli (106 CFU) andE. coli (106 CFU) 
grown in the presence or absence of ampicillin were screened 
with the Au-NP on a 96-well plate using a microtiter plate 
reader. Addition of Con A, followed by a 30-min incubation at 
25° C., resulted in distinct changes of the surface plasmon 10 
band, similar to those described above (FIG. SA) with stan-
dard errors ofless than 0.6 nm. This allowed the categoriza-
tion of the samples in inhibitory (heat-inactivation and 64 µg 
ampicillin) or non-inhibitory (2 and 0 µg ampicillin) cohorts 
(FIG. 9), demonstrating the capability of our method to 15 
screen multiple samples and assess various compounds' anti-
microbial activity simultaneously in a high-throughput for-
mat. 
10 
were autoclaved, in order to heat inactivate the bacteria and 
halt their metabolic reactions. Then, 10 µL aliquots of these 
samples were incubated with IO NPs, as described above. 
Addition of Con A (1 µg/µL) resulted in nanoassembly for-
mation, yet with no statistically significant differences (FIG. 
13). Considering these data, we concluded that the nanopar-
ticle technology can sense the starch levels and bacterial 
metabolism, and not the bacteria per se. 
Then, utilizing the IO NPs, we determined ampicillin's 
MIC. Specifically, E. coli (106 CPUs) were incubated for 2 
hours at 37° C. in MH broth, in the presence of different 
concentrations of ampicillin. Then, 10 µL specimens of these 
samples were incubated with IO NPs, as described above. In 
the absence of Con A, all samples had identical T2 values, 
indicating that the presence of bacteria and antibiotic does not 
affect the spin-spin relaxation time of the nanoparticle sus-
pension (FIG. 14). However, in the presence of Con A and 
after a 30-minute incubation at room temperature, distinct 
changes were observed (FIG. 15A). Specifically, the mag-Dextran-Coated Iron Oxide Nanoparticles for Antimicrobial 
Susceptibility: 
First, we wanted to determine if magnetic IO NPs coated 
with dextran could be used to determine and quantify the 
levels of a polysaccharide (starch) in bacterial culture media. 
Specifically, 190 µl ofIO NPs (9.5 µLnanoparticles [0.685 µg 
Fe/µL] in 180.5 µL deionized water) were inoculated with 10 
µL specimens of starch-containing growth media. Ten µL of 
ConcanavalinA (1 µg/µL) were added, and then the samples 
were incubated at room temperature for various time inter-
vals. The samples were examined in a Bruker 0.47 T (20 
MHz) magnetic relaxometer (The MiniSpec, Bruker), and the 
individual sample's changes in spin-spin relaxation times 
(llT2) were determined based on the formula: 
20 netic-relaxation-determined minimum inhibitory concentra-
tion was 8 µg, as at this concentration we observed a drastic 
change in the values of llT2. Confirmation of the T2-derived 
minimum inhibitory concentration was achieved through the 
turbidity test, described before. Notably, both the T2- and 
25 turbidity-derived concentrations were identical (FIG. 15B). 
We then determined the antibiotic susceptibility or resis-
tance of other bacteria utilizing the IO NPs. Shigella sonnei 
(106 CPUs) and Serratia marcescens (106 CPUs), grown in 
pure cultures, were incubated for 2 hours at 37° C. in MH 
I fl T2incubation time -fl T2prior ConA I . The 0 btained data indicated 
that the changes in fl T2 depend on the starch concentration, 
under concanavalin-induced assembled conditions (FIG. 10 ). 
The observed behavior supported the hypothesis that mag-
netic nanoparticles affect the spin-spin relaxation times of 
adjacent water protons in a dose-dependent mamier, associ-
ated with the levels of carbohydrates within a solution, under 
assembled conditions. 
30 broth, in the presence of different concentrations of ampicil-
lin. Ten µL specimens of these samples were incubated with 
IO NPs, as described above. In the absence of Con A, all 
samples had identical T2 values. Addition of Con A, followed 
by a 30-minute incubation at room temperature, resulted in 
35 different patterns between the two microorganisms (FIGS. 16 
and 17). Specifically, the magnetic-relaxation-determined 
minimum inhibitory concentration was 8 µg for Shigella son-
nei (FIG. 16), whereas Serratia marcescens was found to be 
resistant to ampicillin, as all samples exhibited similar 
Next, as bacteria utilize carbohydrates in their metabolic 
pathways, we hypothesized that any variations in the carbo-
hydrate concentrations attributed to bacterial growth should 
40 changes in the T2 (FIG. 17). Confirmation of the T2-derived 
minimum inhibitory concentration was achieved through the 
turbidity test, yielding identical results to the T2-mediated 
ones. 
be observable, using a known amount of dextran-coated IO 
NPs and Con A. Hence, the changes in T2 of the nanopar- 45 
ticles' suspension should have been related to the extent of 
carbohydrates consumption by bacteria. Therefore, the more 
bacteria present in a suspension the higher the consumption 
and depletion of carbohydrates should have been. In order to 
test this hypothesis, samples of various CFU loads of log- 50 
phase E. coli were incubated for 1 hour at 3 7° C. in MH broth, 
to allow carbohydrate (starch) consumption. Then, the 
samples were autoclaved, and 10 µl aliquots were added to 
190 µL of dextran-coated IO NPs (9.5 µL nanoparticles 
[0.685 µg Fe/µL] in 180.5 µL deionized water). Before addi- 55 
tion of Con A, all samples exhibited the same T2 (FIG. 11). 
Addition of Con A (1 µg/µL) induced nano-assembly forma-
tion, resulting in dose-dependent changes in T2 (FIG. 12). 
The more pronounced changes (higher llT2) were observed 
in samples with higher bacterial loads, due to the higher, more 60 
extensive consumption of starch. 
Lastly, due to the fact that many bacteria can either cause 
septicemia or require growth in optically turbid media, it is 
important to assess bacterial susceptibility in these complex 
matrices. However, most current methods cannot be utilized 
for the detection of molecular targets and assessment of anti-
microbial susceptibility in blood, due to the strong absor-
bance and scattering from the matrix's constituents, includ-
ing platelets and red blood cells. Therefore, considering these 
drawbacks and the facts that bacterial isolation is a major 
limitation step in diagnosis and that certain pathogenic micro-
organisms require growth in specialized media, we investi-
gated whether the dextran-coated polysaccharide nanosen-
sors could assess antimicrobial susceptibility in blood. 
Recently, we reported the high-throughput bacterial suscep-
tibility determination, using the surface plasmon band shifts 
of gold nanoparticles. However, this method cannot be used 
in opaque media, such as blood, due to the intrinsic optical 
properties of the matrix, masking the nanoparticles' plas-
monic band. To investigate this, we usedE. coli and S. marce-
scens cultures suspended in blood-supplemented MH broth 
and incubated in the presence of ampicillin for 2 hours at 3 7° 
In order to determine if indeed the observed differences 
were attributed to the consumption of starch, and not to the 
populations of bacteria present per se, we incubated various 
amounts of E. coli in MH broth with 1.5 mg/mL starch con-
centration, for 10 minutes at 37° C., in order to prevent bac-
terial cell division. Immediately after incubation, the samples 
65 C. Aliquots of these cultures (10 µL) were obtained and added 
into the dextran-coated polysaccharide nanosensors working 
solution, followed by 10 µL ConA treatment (1 µg/µL).After 
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45 minutes following Con A addition at room temperature, 
we determined that the E. coli 's ampicillin MIC was 8 µg, 
without observing any nanoparticle precipitation. Addition-
ally, the S. marcescens' drug resistance was identified after an 
hour-long incubation at 25° C. These data were published in 
the above-referenced paper in Plos One, September 2008, 
Vol. 3, Issue 9, e3253;an Internet publication available at 
www.plosone.org. 
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resistant to ampicillin, further corroborating the findings that 
the non-competition assay format provides faster results than 
the competition-based assay of the dextran-coated nanosen-
sors (FIG. 20B). 
The Con A-conjugated polysaccharide nanosensor assay 
yields faster results, without compromising sensitivity and 
reliability, due to faster binding kinetics. Also, as there is no 
need forthe addition of a second reagent (ConA), this format 
might be particularly useful for point of-care diagnostics and Antimicrobial Susceptibility Assessment Using Concanava-
lin A-Conjugated Polysaccharide Nano sensors 10 applications in the field. 
Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven-
tion and although specific terms may have been employed, the 
terms are used in a descriptive sense only and not for purposes 
15 of limitation. The invention has been described in consider-
Often times a slight modification in the nanosensors' 
design and/or the protocol followed can result in significant 
improvements in either the sensitivity or speed of the assay. 
Therefore, we hypothesized whether conjugating Con A to 
the surface of the magnetic nanoparticles would allow for 
faster kinetics and shorter the detection time. For these 
experiments, we conjugated Con A directly to aminated 
silica-coated iron oxide nanoparticles. We chose silica-coated 
instead of dextran-coated iron oxide nanoparticles to avoid 
possible cross reaction with the dextran on the nanoparticle' s 
surface. In this non-competition assay (FIG. 18), the Con 
A-conjugated silica coated nanosensors would facilitate the 
direct sensing of the levels of carbohydrates in solution, as 
opposed to the competition assay that requires two reagents; 
the dextran-coatednanoparticles and the ConA for successful 25 
sensing. The aminated silica-coated nanoparticles were syn-
thesized using a modified water-based synthetic protocol. 
The resulting nanoparticles were monodispersed, having a 
diameter of 145 nm and an R2 relaxivity of 225 mM- 1s- 1 . 
able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica-
tions and changes can be made within the spirit and scope of 
the invention as described in the foregoing specification and 
20 as defined in the appended claims. 
That which is claimed: 
1. A method of testing bacterial cells for antimicrobial 
susceptibility, the method comprising: 
mixing a suspension of bacterial cells in a non-nutrient 
medium with an antimicrobial and a carbohydrate 
usable by the bacterial cells; 
adding iron oxide nanoparticles and a lectin to the mixture; 
and 
monitoring a parameter associated with the nanoparticles 
responsive to use of the carbohydrate by the bacterial 
cells. 
2. The method of claim 1, wherein the antimicrobial com-
prises a pharmaceutical administrable to a human or animal 
patient. 
3. The method of claim 1, wherein the iron oxide nanopar-
ticles nanoparticles comprise rod-shaped nanoparticles. 
4. The method of claim 1, wherein the lectin is conjugated 
to the surface of the iron oxide nanoparticles before adding. 
5. The method of claim 1, wherein the iron oxide nanopar-
ticles further comprise a coating polymer which bears the 
lectin. 
In our first set of experiments with the aminated silica- 30 
coated nanoparticles, we determined whether these nanopar-
ticles clustered non-specifically in the presence of Con A in 
solution. As expected, we observed that Con A did not induce 
any changes in the relaxation times of the nanoparticles. This 
demonstrates that the silica coating on these nanoparticles 35 
lacks any carbohydrate epitopes, rendering them suitable for 
the noncompetition-based sensing of carbohydrates. There-
fore, we conjugated Con A to the aminated silica-coated 
nanoparticles, via carbodiimide chemistry, resulting in Con 
A-carrying nanoparticles with a hydrodynamic diameter of, 40 
160 nm (R2=225 mM- 1s-1, [ConA]=0.03 µg/µL). First, we 
compared the kinetic profiles of the dextran-coated nanosen-
sors and Con A-conjugated nanosensors using bacterial E. 
coli blood cultures (106 CFU grown in the presence of 2 µg 
ampicillin). Interestingly, we found that the non-competition 
assay with the ConA-conjugatednanosensors (FIG.19, curve 
6. The method of claim 1, wherein the iron oxide nanopar-
ticles further comprise a coating of amino-silica bearing the 
45 
lectin. 
7. The method of claim 1, wherein the iron oxide nanopar-
ticles further comprise a coating polyacrylic acid polymer 
bearing the lectin. 
B) provided faster results than the competition assay that 
utilizes the dextran-coated nanosensors (FIG. 19, curve A). 
Specifically, the competition assay format reached its end-
point after a 45-minute incubation, whereas the non-compe- 50 
ti ti on assay reaches its end-point within 5 minutes upon addi-
tion of the bacterial sample. These findings support our 
hypothesis of achieving faster kinetics due to the direct con-
jugation of Con A to the nanoparticles. 
Then, we examined if MIC determination can be achieved 55 
using these Con A-conjugated nano sensors, in blood cultures 
of E. coli and S. marcescens. Immediately upon addition of 
the bacterial sample into the nanoparticle solution, distinct 
changes in the T2 were observed. Specifically, within 5 min-
utes the Con A nanosensors were able to determine thatE. coli 60 
had an ampicillin MIC of 8 µg (FIG. 20A), in line with the 
data from the dextrancoated nanosensors in the competition 
assay or the turbidity test. Likewise, within 5 minutes the Con 
A-conjugated nanosensors assessed that S. marcescens was 
8. The method of claim 1, wherein the lectin has a high 
binding affinity for the carbohydrate. 
9. The method of claim 1, wherein the lectin comprises 
concanavalin A. 
10. The method of claim 1, wherein the parameter is moni-
tored by nuclear magnetic resonance. 
11. The method of claim 1, wherein the parameter is moni-
tored by the nuclear magnetic resonance T2 water relaxation 
time. 
12. The method of claim 1, wherein the magnetic relax-
ation parameter comprises an increase or a decrease in T2 
water relaxation time by nuclear magnetic resonance. 
13. The method of claim 1, wherein the iron oxide nano-
particles are capable of causing an increase or a decrease in 
the T2 of water. 
* * * * * 
